2011-06-21T11:43:57-05:00 2010-12-31 SOBEL AND CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2010-01-01 820547746 LIFE RAFT GROUP INC LIFE 9738379092 155 ROUTE 46 WEST NO 2ND FL WAYNE NJ 07470 NORMAN J SCHERZER 9738379092 2011-06-14 1 RON MATAN 9739949494 2011-06-14 2010 2016-02-24 21:20:13Z NORMAN J SCHERZER 155 ROUTE 46 WEST 2ND FLOOR WAYNE NJ 07470 2910666 0 X WWW.LIFERAFTGROUP.ORG X 2002 NJ THE MISSION OF THE LIFE RAFT GROUP IS TO ENSURE SURVIVAL OF GIST PATIENTS. 14 13 19 32 0 0 2960796 2740321 0 0 53529 36782 64645 61851 3078970 2838954 826837 1673043 0 0 539366 728117 0 0 46491 402557 434157 1768760 2835317 1310210 3637 5840673 5898418 33682 87790 5806991 5810628 X THE MISSION OF THE LIFE RAFT GROUP (LRG) IS TO ENSURE SURVIVAL OF GIST PATIENTS WHILE MAINTAINING THE QUALITY OF THEIR LIVES. TO ACCOMPLISH THIS MISSION, THE LIFE RAFT GROUP DEVOTES ITS EFFORTS TO FIVE MAJOR AREAS: RESEARCH, TREATMENT, SURVEILLANCE, INFORMATION & SUPPORT, PATIENT OUTREACH & ASSISTANCE, AND ADVOCACY. 0 0 2556372 RESEARCH: THE LIFE RAFT GROUP DIRECTS RESEARCH TO FIND A CURE FOR A RARE CANCER AND HELPS THOSE AFFECTED THROUGH SUPPORT AND ADVOCACY UNTIL WE DO. THE LIFE RAFT GROUP DIRECTS AN INNOVATIVE RESEARCH PROGRAM THAT SUPPORTS THE COORDINATED EFFORTS OF A WORLD CLASS RESEARCH TEAM, A COLLABORATIVE TISSUE BANK AND A UNIQUE PATIENT REGISTRY WHICH TRACKS THE CLINICAL HISTORIES OF OVER 1200 PATIENTS WITH GIST. RESEARCHERS ARE REQUIRED TO COLLABORATE RATHER THAN TO COMPETE, INCLUDING TWICE A YEAR IN PERSON MEETINGS. RESEARCH GRANTS ARE CONSTRUCTED TO MINIMIZE OVERHEAD, INCLUDING ELIMINATION OF INDIRECT COSTS. 185963 INFORMATION, EDUCATION AND SUPPORT: THE LIFE RAFT GROUP DIRECTS RESEARCH TO FIND A CURE FOR A RARE CANCER AND HELPS THOSE AFFECTED THROUGH THE SUPPORT AND ADVOCACY UNTIL WE DO.THE LIFE RAFT GROUP PROVIDES ACCURATE AND TIMELY INFORMATION TO PATIENTS, CAREGIVERS AND MEDICAL PROFESSIONALS AROUND THE WORLD. THROUGH THE PUBLICATION OF NEWSLETTERS, INFORMATION ALERTS AND PAMPHLETS THE CONDUCT OF WEBCASTS AND EDUCATIONAL SEMINARS AND THE MAINTENANCE OF SEVERAL WEBSITES THE LIFE RAFT GROUP KEEPS LAYPERSONS AND MEDICAL PROFESSIONALS INFORMED ABOUT THE LATEST TREATMENT OPTIONS, INCLUDING A WORLDWIDE DIRECTORY OF PHYSICIAN SPECIALISTS AND CLINICAL TRIALS. IN ADDITION THE LIFE RAFT GROUP SPONSORS A HOST OF MULTILINGUAL FORUMS PERMITTING PATIENTS AND CAREGIVERS TO TALK AND SUPPORT EACH OTHER IN THEIR OWN NATIVE LANGUAGE. THESE INCLUDE ENGLISH, SPANISH, GERMAN AND DUTCH, WITH MORE DEVELOPMENT. FINALLY, THE LIFE RAFT GROUP PROVIDES ONE ON ONE CONSULTATION TO PATIENTS AND CAREGIVERS SEEKING STRATEGIC TREATMENT OPTIONS TO DISCUSS WITH THEIR PHYSICANS AS WELL AS LOGISTICAL SUPPORT TO ACCESS TREATMENT. 2742335 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 1 19 1 0 0 0 0 0 1 1 0 0 X 14 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NJ X X NORMAN J SCHERZER 9738379092 155 ROUTE 46 WEST 2ND FL WAYNE NJ 07470 JERRY CUDZIL 1.00 X 0 0 0 RAYMOND MONTAGUE 1.00 X 0 0 0 ROBERT BOOK 1.00 X 0 0 0 STANN BUNN 1.00 X 0 0 0 JIM HUGHES 1.00 X 0 0 0 GERALD KNAPP 1.00 X 0 0 0 JOHN POSS 1.00 X 0 0 0 MARIETTA ROBINSON 1.00 X 0 0 0 RODRIGO SALAS 1.00 X 0 0 0 SILVIA WILLIAMS-STEINHILBER 1.00 X 0 0 0 CHRIS CARLEY 1.00 X 0 0 0 LAWRENCE D SELKOVITS 1.00 X 0 0 0 NORMAN J SCHERZER 35.00 X X 92351 0 9928 DAVID SAFFORD 1.00 X 0 0 0 92351 0 9928 0 0 0 0 0 33926 2706395 2740321 36782 36782 26490 33926 44595 -18105 -18105 90937 27117 63820 63820 HONORARIUM & CONSULTAT 611710 16056 16056 OTHER REVENUE 900099 80 80 16136 2838954 16136 0 82497 1673043 1673043 102279 94097 4091 4091 495734 456074 19830 19830 13231 12173 529 529 51684 47550 2067 2067 65189 59973 2608 2608 7800 6864 468 468 103355 95399 3978 3978 33916 31202 1357 1357 20434 18800 817 817 77830 71604 3113 3113 108285 99623 4331 4331 20570 18924 823 823 9616 8846 385 385 PRINTING AND PUBLICATIO 27035 24873 1081 1081 POSTAGE 11708 10772 468 468 COMMUNICATIONS 10901 10029 436 436 MARKETING AND PR 2441 2245 98 98 SECURITY 266 244 11 11 2835317 2742335 46491 46491 165237 11988 5596885 5805690 7475 7475 112676 54362 47648 58314 5399 18029 14951 5840673 5898418 33682 87790 33682 87790 X 5806991 5810628 5806991 5810628 5840673 5898418 3637 X X 0 1 1 X 0 X 572300 749685 947608 2960796 717871 5948260 25293 26490 51783 572300 749685 972901 2960796 744361 6000043 1750745 323692 2074437 0 1750745 323692 2074437 3925606 96612 84889 104796 53529 36782 376608 96612 84889 104796 53529 36782 376608 16136 16136 668912 834574 1077697 3014325 797279 6392787 0.61410 0.94120 0.05890 0.05880 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 92939 40579 52360 19737 13783 5954 58314 2838954 2835317 3637 0 3637 2838954 0 2838954 0 2838954 2835317 0 2835317 0 2835317 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE ORGANIZATION IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C) (3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION FOLLOWS ACCOUNTING STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. TAX RETURNS FOR CERTAIN YEARS ARE SUBJECT TO AUDIT BY FEDERAL AND STATE JURISDICTIONS. AT DECEMBER 31, 2010, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES THAT ARE EXPECTED TO HAVE A MATERIAL IMPACT ON THE ORGANIZATION'S 2010 FINANCIAL STATEMENTS. PART XIII, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENTS INDIRECT EXPENSES 1 EUROPE GRANTS TO RECIPIENTS IN REGION. PROGRAM FUNDING FOR RESEARCH FOR GIST PATIENTS. 200000 0 0 0 200000 0 200000 X EUROPE TO CONDUCT RESEARCH TO DISCOVER REASONS FOR TREATMENT RESISTANCE. 100000 WIRE TRANSFER EUROPE TO CONDUCT RESEARCH TO DISCOVER REASONS FOR TREATMENT RESISTANCE. 100000 WIRE TRANSFER 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: THE GRANT RECIPIENTS MUST SUBMIT REGULAR PROGRESS REPORTS, BUDGET REPORTS AND COPIES OF ARTICLES AND PRESENTATIONS IN WHICH THE PRINCIPAL INVESTIGATOR IS LISTED AS THE AUTHOR, AS WELL AS PARTICIPATE IN A SPECIFIED NUMBER OF IN-PERSON AND TELECONFERENCE MEETINGS EVERY TWELVE MONTHS. METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: WIRE TRANSFER LIFE FEST 60416 33926 26490 10060 8455 26080 60416 33926 26490 10060 8455 26080 44595 -18105 90937 0 11669 12523 2925 1 90937 11669 12523 2925 27117 63820 NY 1 0 1 0 1.00000 NORMAN J SCHERZER 155 ROUTE 46 WEST 2ND FL WAYNE NJ 07470 0 TRICIA MCALEER X 0 1 UNIVERSITY OF PITTSBURGH 5117 CENTRE AVENUE PITTSBURGH PA 15213 250965591 501(C)(3) 165500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. PORTLAND VA RESEARCH FOUNDATION 3710 US VETERANS HOSPITAL ROAD PORTLAND OR 97201 943090170 501(C)(3) 140500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. CLEVELAND CLINIC 9500 EUCLID AVENUE L25 CLEVELAND OH 44195 340714575 501(C)(3) 165500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10021 912154267 501(C)(3) 231000 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. STANFORD UNIVERSITY 300 PASTEUR DRIVE L-225 STANFORD CA 94305 941156365 501(C)(3) 128543 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. BRIGHAM & WOMEN'S HOSPITAL 75 FRANCIS STREET THORN 5TH FLOOR BOSTON MA 02115 042312909 501(C)(3) 42500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. PORTLAND VA RESEARCH FOUNDATION PO BOX 69539 PORTLAND OR 97239 943090170 501(C)(3) 140500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. 7 7 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: THE GRANT RECIPIENTS MUST SUBMIT REGULAR PROGRESS REPORTS, BUDGET REPORTS AND COPIES OF ARTICLES AND PRESENTATIONS IN WHICH THE PRINCIPAL INVESTIGATOR IS LISTED AS THE AUTHOR, AS WELL AS PARTICIPATE IN A SPECIFIED NUMBER OF IN-PERSON AND TELECONFERENCE MEETINGS EVERY TWELVE MONTHS. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS FIRST REVIEWED BY THE DIRECTOR OF ADMINISTRATION, THEN BY THE EXECUTIVE DIRECTOR AFTER DISCUSSION WITH THE DIRECTOR OF ADMINISTRATION. IT IS ALSO SENT TO THE BOARD TREASURER AND THE BOARD PRESIDENT AND ANY QUESTIONS OR COMMENTS ARE DISCUSSED WITH THE EXECUTIVE DIRECTOR AND DIRECTOR OF ADMINISTRATION. FORM 990, PART VI, SECTION B, LINE 12C POTENTIAL CONFLICTS ARE DISCUSSED ANNUALLY AT A BOARD MEETING. FORM 990, PART VI, SECTION B, LINE 15 AT LEAST ONCE A YEAR THE EXECUTIVE DIRECTOR MEETS TO REVIEW AND DISCUSS REPORTS OF COMPARABLE NON-PROFIT SALARIES PREPARED BY INDEPENDENT ORGANIZATIONS. THIS REVIEW PROVIDES THE GUIDELINES FOR REVIEWING AND APPROVING ANY SALARY RECOMMENDATIONS PROPOSED BY THE EXECUTIVE DIRECTOR. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION MAKES ITS FORM 1023 AND 990 AVAILABLE FOR PUBLIC INSPECTION THROUGH THE ORGANIZATION'S WEBSITE, AT ANOTHER'S WEBSITE CALLED GUIDESTAR.COM AND UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, INCLUDING A CONFLICT OF INTEREST POLICY (PART OF BY-LAWS), AND FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE AND ARE MADE AVAILABLE AS INDIVIDUAL DOCUMENTS UPON REQUEST. THE ORGANIZATION'S PROCESS FOR OVERSIGHT OF THE ANNUAL AUDIT HAS NOT CHANGED FROM THE PRIOR YEAR.